<DOC>
	<DOC>NCT01710813</DOC>
	<brief_summary>To collect uniform and meaningful data on patients with Pompe disease who experience anaphylaxis, severe allergic reactions, and/or signals of severe cutaneous and/or systemic immune complex-mediated reactions following treatment with alglucosidase alfa.</brief_summary>
	<brief_title>Alglucosidase Alfa Pompe Safety Sub-Registry</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Antigen-Antibody Complex</mesh_term>
	<criteria>The patient must be enrolled in the Pompe Registry; Provide a signed patient information and authorization form; Have a confirmed diagnosis of Pompe disease (confirmation of diagnosis is defined as documented GAA enzyme deficiency from any tissue source and/or documentation of 2 GAA gene mutations); Be na√Øve to and plan to be treated with alglucosidase alfa at or prior to enrollment, or are being treated with alglucosidase alfa. Patients will be excluded if they have received an investigational drug (excluding alglucosidase alfa) within 30 days prior to signing a Safety SubRegistry Patient Information and Authorization form, or if they are taking or plan to take any investigational product while enrolled in the Safety SubRegistry.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>pompe disease</keyword>
	<keyword>alglucosidase alfa</keyword>
	<keyword>anaphylaxis</keyword>
	<keyword>severe cutaneous</keyword>
	<keyword>systemic immune complex-mediated reactions</keyword>
</DOC>